Concepedia

Yue Ren

YR

Statistics

Publications

6

Citations

320

H-Index

6

Active since

2022

Affiliations

Dana-Farber Cancer Institute(Current)

Harvard University

Beth Israel Deaconess Medical Center

UNC Lineberger Comprehensive Cancer Center

Weill Cornell Medicine

Yue Ren is an author at Dana-Farber Cancer Institute specializing in pharmacology, medicine, and oncology.

ORCID

Publications per year

2022–2024

6

Publications

6

PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer

Erica L. Mayer, Yue Ren, Nikhil Wagle et al. · Journal of Clinical Oncology · 2024 · 109 citations

, , +17

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance

Aishath Naeem, Filippo Utro, Qing Wang et al. · Blood Advances · 2022 · 79 citations · Full text

, , +14

Abstract GS3-06: GS3-06 Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer

Erica L. Mayer, Yue Ren, Nikhil Wagle et al. · Cancer Research · 2023 · 57 citations

, , +16

Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease

Matthew S. Davids, Christine E. Ryan, Benjamin L. Lampson et al. · Journal of Clinical Oncology · 2024 · 40 citations · Full text

, , +17

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Christine E. Ryan, Benjamin L. Lampson, Svitlana Tyekucheva et al. · Blood · 2022 · 23 citations

, , +6

1–5 of 6